Selected publications
-
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Blood.
2019
Academic Article
GET IT
Times cited: 10 -
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Journal of Clinical Oncology.
2019
Academic Article
GET IT
Times cited: 12 -
Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015.
Hematological Oncology.
2017
Review
GET IT
Times cited: 3 -
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: A long-term follow-up study of the US intergroup phase III trial E2997.
Leukemia and Lymphoma.
2015
Academic Article
GET IT
Times cited: 5 -
Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.
Cancer Genetics.
2014
Academic Article
GET IT
Times cited: 4 -
EZH2 mutations are frequent and represent an early event in follicular lymphoma.
Blood.
2013
Academic Article
GET IT
Times cited: 117 -
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Leukemia and Lymphoma.
2012
Academic Article
GET IT
Times cited: 47 -
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US intergroup phase III trial E2997.
Journal of Clinical Oncology.
2007
Academic Article
GET IT
Times cited: 270 -
Sustained complete remission of CLL associated with the use of a Chinese herbal extract: Case report and mechanistic analysis.
Leukemia Research.
2003
Academic Article
GET IT
Times cited: 6